A guidance statement worth unpacking
Big Technologies (LSE:BIG), which trades as Buddi, has issued no trading news since its interim results on 14 September 2026; its most recent announcements were two Shareholder notifications on 9 November and litigation updates in October. That makes the interim statement the best guide to the year, and one line in it deserves closer reading: the board said it was confident 2026 results would be marginally ahead of market consensus.
Unusually, the company (LSE:BIG) published the consensus it was referring to, which allows investors to work out what the second half needs to deliver.
The first-half base
For the six months to 30 June 2026, Revenue was £26.9m against £24.8m a year earlier, or 6% higher at constant currency. Annual Recurring Revenue reached £53.2m, up 5% at constant currency, helped by wins in the Americas and Europe. Adjusted EBITDA rose 14% to £14.2m, a Margin of about 53%, and adjusted free Cash Flow was £9.6m, against £6.7m a year earlier.
Cash stood at £67.1m after £33.4m of settlement payments linked to the Buddi litigation, which was settled for £38.5m in January. Statutory profit for the half was £7.7m, compared with a loss of £28.9m when large legal provisions were booked in 2025.
What the published consensus implies
The company (LSE:BIG) said five analysts forecast 2026 revenue of £50.5m to £52.2m, with a consensus of £51.1m, and adjusted EBITDA of £24.7m to £25.9m, with a consensus of £25.3m.
Consensus therefore assumes second-half revenue of about £24.2m and adjusted EBITDA of about £11.1m, both below the first half. Being marginally ahead of those figures would still leave the second half lighter than the first on both measures, unless the margin of outperformance is larger than the wording suggests. The interim statement did not explain the phasing, so investors should not assume a seasonal pattern the company has not described.
Contracts that support the outlook
Management pointed to a seven-year contract with Chile's Gendarmerie, won with partner Sonda, expected to generate about US$26m in total, plus a two-year award in Peru worth about US$0.6m and a three-year renewal in Guatemala. The group recorded 23 US contract wins in the half. On 22 September it added a two-year extension with New Zealand's Department of Corrections, running to August 2029.
Alcohol monitoring products, AlcoTag and AlcoBreath, were described as higher-margin and growing fastest in the US, the group's largest addressable market. A smaller second version of AlcoTag is in development. If these products take a larger share of new US business, they could help protect group margins as lower-margin full-service contracts such as Northern Ireland grow.
Factors to watch
Net revenue retention slipped to 98% from 102%, which the company attributed to an Australian immigration contract ending after a legal challenge; excluding it, retention was 100%. Gross margin eased to 66.7% from 67.5%, reflecting the lower-margin Northern Ireland contract. New contracts only enter ARR once revenue begins, so timing of the Chile rollout matters.
Legal costs remain a variable. The group is still pursuing separate proceedings against founder Sara Murray, has recognised no potential recoveries and will expense future fees as incurred; non-recurring legal cash outflows were £2.6m in the half. Leadership is also interim, with an acting chief executive and interim chair in post.
What to watch next
The company has not yet announced a date for its full-year 2026 results or a year-end trading update. When it does, the key tests will be whether revenue lands above the published £51.1m consensus, how quickly Chile contributes to ARR, and whether litigation costs continue to fall. Investors will also look for any decision on permanent board leadership, and for evidence that underlying administrative costs, which fell to £6.6m in the half from £7.2m, stay contained.






Please wait processing your request...